Drugs / CP-609,754
CP-609,754
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00903253 | May → Sep 2009 | — | Link Medicine Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00006085 | Jun 2000 → ? | cancer of unknown primary site | H. Lee Moffitt Cancer Center and Research Institute | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01013610 Comparator | Nov 2009 → Mar 2011 | Alzheimer disease | Link Medicine Corporation | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CP-609,754 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006085 ↗ |
| Known as | LNK-754 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01013610 ↗ |
| Known as | OSI-754 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297367 ↗ |
| Action | Inhibit | “a Farnesyl Transferase Inhibitor” NCT00006085 ↗ |
| Modality | Small molecule | — CHEMBL4297367 ↗ |
| Route | Oral | “Patients receive oral CP-609,754 1-2 times daily” NCT00006085 ↗ |